TW273509B - Method for rapidly building image space relation using plane filtering limitation - Google Patents

Method for rapidly building image space relation using plane filtering limitation Download PDF

Info

Publication number
TW273509B
TW273509B TW083111836A TW83111836A TW273509B TW 273509 B TW273509 B TW 273509B TW 083111836 A TW083111836 A TW 083111836A TW 83111836 A TW83111836 A TW 83111836A TW 273509 B TW273509 B TW 273509B
Authority
TW
Taiwan
Prior art keywords
compound
formula
cns
patent application
ministry
Prior art date
Application number
TW083111836A
Other languages
English (en)
Chinese (zh)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of TW273509B publication Critical patent/TW273509B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Seasonings (AREA)
TW083111836A 1993-12-21 1994-12-19 Method for rapidly building image space relation using plane filtering limitation TW273509B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/170,944 US5476862A (en) 1993-12-21 1993-12-21 Methods of increasing thrombomodulin expression

Publications (1)

Publication Number Publication Date
TW273509B true TW273509B (en) 1996-04-01

Family

ID=22621914

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083111836A TW273509B (en) 1993-12-21 1994-12-19 Method for rapidly building image space relation using plane filtering limitation

Country Status (22)

Country Link
US (2) US5476862A (da)
EP (1) EP0659427B1 (da)
JP (1) JPH07196496A (da)
KR (1) KR950016727A (da)
CN (1) CN1044679C (da)
AT (1) ATE220904T1 (da)
AU (1) AU692194B2 (da)
CA (1) CA2138490A1 (da)
CZ (1) CZ288983B6 (da)
DE (1) DE69431035T2 (da)
DK (1) DK0659427T3 (da)
ES (1) ES2180564T3 (da)
HU (1) HUT71470A (da)
IL (1) IL112036A (da)
NO (1) NO310596B1 (da)
NZ (1) NZ270169A (da)
PH (1) PH31325A (da)
PT (1) PT659427E (da)
RU (2) RU2125450C1 (da)
TW (1) TW273509B (da)
UA (1) UA27910C2 (da)
ZA (1) ZA9410079B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US6545027B1 (en) * 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
DE69622472T2 (de) * 1995-06-07 2003-02-06 Lilly Co Eli Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
US6103740A (en) * 1997-08-21 2000-08-15 Eli Lilly And Company Methods for lowering platelet counts
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
US6353003B1 (en) * 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
AU2001292308A1 (en) * 2000-09-30 2002-04-15 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for hemolytic anemia
US20060148695A1 (en) * 2005-01-03 2006-07-06 National Cheng Kung University Novel angiogenic composition and use thereof
CA2680737C (en) * 2007-03-21 2015-12-15 Emisphere Technologies, Inc. Allyloxy and alkyloxy benzoic acid delivery agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
AU672182B2 (en) * 1991-11-27 1996-09-26 Novo Nordisk A/S Piperidine derivatives and their use in treating psychosis

Also Published As

Publication number Publication date
NO310596B1 (no) 2001-07-30
CZ288983B6 (cs) 2001-10-17
RU2125450C1 (ru) 1999-01-27
PT659427E (pt) 2002-11-29
DE69431035T2 (de) 2003-01-30
NZ270169A (en) 1997-07-27
US5700815A (en) 1997-12-23
CA2138490A1 (en) 1995-06-22
NO944915L (no) 1995-06-22
KR950016727A (ko) 1995-07-20
JPH07196496A (ja) 1995-08-01
ES2180564T3 (es) 2003-02-16
NO944915D0 (no) 1994-12-19
CZ321194A3 (en) 1995-08-16
ZA9410079B (en) 1996-06-19
EP0659427B1 (en) 2002-07-24
CN1108932A (zh) 1995-09-27
US5476862A (en) 1995-12-19
DE69431035D1 (de) 2002-08-29
AU8155494A (en) 1995-06-29
ATE220904T1 (de) 2002-08-15
UA27910C2 (uk) 2000-10-16
CN1044679C (zh) 1999-08-18
RU94044356A (ru) 1996-10-10
AU692194B2 (en) 1998-06-04
PH31325A (en) 1998-07-06
IL112036A0 (en) 1995-03-15
DK0659427T3 (da) 2002-09-02
EP0659427A1 (en) 1995-06-28
HUT71470A (en) 1995-11-28
HU9403664D0 (en) 1995-02-28
IL112036A (en) 1999-01-26
RU2190405C2 (ru) 2002-10-10

Similar Documents

Publication Publication Date Title
TW273509B (en) Method for rapidly building image space relation using plane filtering limitation
EP1586322B1 (en) Compositions comprising thalodimide and dexamethasone for the treatment of cancer& x9;
KR101472765B1 (ko) 경구용 Ｘａ 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Ｘａ 인자 억제제를 사용하는 혈전증의 치료 방법
TW321601B (da)
CN1315803C (zh) 作为蛋白酶抑制剂的氨基吡啶基－,氨基胍基－和烷氧基胍基－取代苯基乙酰胺
MXPA03004699A (es) Sintesis de 3-amino-talidomida y sus enantiomeros.
JPH10513475A (ja) 細胞−細胞接着を阻止する方法
JP2000510467A (ja) 線維症の病変の修復と予防
TWI251491B (en) Pharmaceutical combinations
JP3963301B2 (ja) テトラヒドロイソキノリン系化合物を含有する薬学的組成物
JPH04503524A (ja) 再潅流損傷の防止又は制限のための薬剤
CA2467451A1 (en) Method for controlling angiogenesis in animals
CN115427043B (zh) FXIa抑制剂化合物或其盐的医药用途
WO2006084200A2 (en) Nitroxides for use in treating or preventing cardiovascular disease
JPH11513665A (ja) プラスミノーゲンアクチベーターインヒビター１の阻害方法
EP0001503B1 (en) Antithrombotic compositions containing benzisothiazolones
AU741720B2 (en) Methods for reducing fibrinogen
BE1004874A4 (fr) Depresseur de l'inhibiteur de l'alpha2-plasmine.
AU707215B2 (en) Thrombolytic agents
JPH01250350A (ja) 循環器用剤
JPH05170690A (ja) ジフェニル炭化水素誘導体を有効成分として含有する血栓溶解促進剤
EP0811377A1 (en) Thrombolytic agent
KR100231978B1 (ko) 아스피린 회합체 및 안티-Xa 올리고사카라이드를 함유하는 조성물과 아스피린 결합물내 안티-XA 올리고사카라이드의 용도
CA2209619A1 (en) Thrombolytic agents
JPS6357404B2 (da)